The US health industry is in the midst of a transformation to a value-outcome system, which is good for a learning health system, explained Lewis G. Sandy, MD, FACP, senior vice president of clinical advancement at UnitedHealth Group.
senior vice president of clinical advancement at UnitedHealth Group
The US health industry is in the midst of a transformation to a value-outcome system, which is good for a learning health system, explained Lewis G. Sandy, MD, FACP, .
The topics of the learning health system, which uses information that comes out of clinical care and can use it to improve the care of patients, was the first plenary session at the ISPOR 20th Annual Meeting in Philadelphia.
"We clearly need a culture change in healthcare generally to focus on patient outcomes and value, and the learning health system is part of that," Dr Sandy said.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More